CXCR2 and neoplasm: Given previous reports of CXCR2 chemokine upregulation in PTEN-deleted prostate tumours10,11,20,23, we interrogated pre-treatment tumour PTEN protein expression (5 patients classed as partial responders, 15 patients classed as non-responders) and pathway gene alteration using a previously described next-generation sequencing (NGS) panel38 (5 patients classed as partial responders, 14 patients classed as non-responders).